In3Bio is a UK based Biotech company that develops a novel approach in oncology, perhaps the best tolerability profile used in oncology. In3Bio obtained the patent on a technological platform of new biological molecules for use in the treatment of solid cancers. In3Bio is currently conducting a Phase I clinical trial in centers in Spain with a combination of EGFR TKI and EGF vaccine. The company has tested small molecule inhibitors in suitable cell lines and has demonstrated that the efficacy of the 15 small molecules tested has benefited significantly from the combination with IN01, one of the patented molecules developed by In3Bio. The company is currently ready to start several phases I clinical trials in 2020 and is developing the preparation of the clinical batch of IN02, another In3Bio molecule.
| Website | http://www.in3bio.com |
| Revenue | $5.7 million |
| Employees | View employees |
| Address | 1 Jalan Sri Hartamas, Kuala Lumpur, Kuala Lumpur 50480, MY |
| Industry | Manufacturing General, Manufacturing |
| Competitors | Moderna Therapeutics, GSK, Pfizer, Novavax, AstraZeneca, Sanofi, Johnson & Johnson, Roche, Merck & Co., Inc., Regeneron +50 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 80 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular In3Bio employee's phone or email?
In3Bio Questions
The In3Bio annual revenue was $5.7 million in 2026.
In3Bio is based in Kuala Lumpur, Kuala Lumpur.
The NAICS codes for In3Bio are [325, 32, 3254].
The SIC codes for In3Bio are [28, 80, 283].
